These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7996426)

  • 1. Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: a study of L-663,581 and its metabolites in rats.
    Lin JH; Chen IW; Lin TH
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1197-202. PubMed ID: 7996426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals.
    Chen IW; Lin JH
    Drug Metab Dispos; 1994; 22(5):693-9. PubMed ID: 7835219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligands.
    Pike A; Cook SM; Watt AP; Scott-Stevens P; Rosahl TW; McKernan RM; Pym LJ; Guiblin A; Moyes C; Sohal B; Atack JR
    Biopharm Drug Dispos; 2007 Sep; 28(6):275-82. PubMed ID: 17570124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. interaction with the gamma-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent.
    Doble A; Canton T; Dreisler S; Piot O; Boireau A; Stutzmann JM; Bardone MC; Rataud J; Roux M; Roussel G
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1213-26. PubMed ID: 8103792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons.
    Witkin JM; Acri JB; Wong G; Gleeson S; Barrett JE
    J Pharmacol Exp Ther; 1996 Apr; 277(1):87-96. PubMed ID: 8613971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.
    Scott-Stevens P; Atack JR; Sohal B; Worboys P
    Biopharm Drug Dispos; 2005 Jan; 26(1):13-20. PubMed ID: 15578749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of benzodiazepine binding to alpha 5 subunit-containing gamma-aminobutyric Acid(A) receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region.
    Li M; Szabo A; Rosenberg HC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):689-96. PubMed ID: 11046107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.
    Rajarao SJ; Platt B; Sukoff SJ; Lin Q; Bender CN; Nieuwenhuijsen BW; Ring RH; Schechter LE; Rosenzweig-Lipson S; Beyer CE
    Neuropeptides; 2007 Oct; 41(5):307-20. PubMed ID: 17637475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The action of the benzodiazepine antagonist Ro 15-1788].
    Doenicke A; Suttmann H; Kapp W; Kugler J; Ebentheuer H
    Anaesthesist; 1984 Aug; 33(8):343-7. PubMed ID: 6148904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of a 14C/3H-labeled GABAA receptor partial agonist in rat, dog and human liver microsomes: evaluation of a dual-radiolabel strategy.
    Shaffer CL; Langer CS
    J Pharm Biomed Anal; 2007 Mar; 43(4):1195-205. PubMed ID: 17150324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolite involvement in bromocriptine-induced prolactin inhibition in rats.
    Valente D; Delaforge M; Urien S; Guivarc'h D; Vienet R; Grognet JM; Ezan E
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1418-24. PubMed ID: 9316855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat.
    Widler P; Fisch HU; Schoch P; Zimmermann A; Schläpfer TE; Reichen J
    Hepatology; 1993 Dec; 18(6):1459-64. PubMed ID: 8080486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imidazenil: a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAA receptors.
    Giusti P; Ducić I; Puia G; Arban R; Walser A; Guidotti A; Costa E
    J Pharmacol Exp Ther; 1993 Aug; 266(2):1018-28. PubMed ID: 8394902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [2-11C]isopropyl-, [1-11C]ethyl-, and [11C]methyl-labeled phenoxyphenyl acetamide derivatives as positron emission tomography ligands for the peripheral benzodiazepine receptor: radiosynthesis, uptake, and in vivo binding in brain.
    Zhang MR; Ogawa M; Maeda J; Ito T; Noguchi J; Kumata K; Okauchi T; Suhara T; Suzuki K
    J Med Chem; 2006 May; 49(9):2735-42. PubMed ID: 16640334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic.
    Dubinsky B; Vaidya AH; Rosenthal DI; Hochman C; Crooke JJ; DeLuca S; DeVine A; Cheo-Isaacs CT; Carter AR; Jordan AD; Reitz AB; Shank RP
    J Pharmacol Exp Ther; 2002 Nov; 303(2):777-90. PubMed ID: 12388665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.
    Kem WR; Mahnir VM; Prokai L; Papke RL; Cao X; LeFrancois S; Wildeboer K; Prokai-Tatrai K; Porter-Papke J; Soti F
    Mol Pharmacol; 2004 Jan; 65(1):56-67. PubMed ID: 14722237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
    Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
    Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
    Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1254-62. PubMed ID: 15743928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro models for the blood-brain barrier.
    Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
    Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.